You Too Can Be An Analyst

We have no intention to belittle the very good work research analysts perform or minimize their training and experience. However, we have found over the years, that investors often have a better sense as to the chances a clinical trial will succeed or whether the FDA will approve a product, perhaps even more than the biotech companies themselves. Partly because they are more distant from the process, investor are often more objective. In this section, You Too Can Be An Analyst, we ask all of you to express your view as to the possible outcome of an event. BiotechWatch will rotate the questions, monitor the results and provide feedback to the larger biotech community.